Revive Therapeutics Ltd.
RVVTF
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 206.60K | 293.20K | 118.50K | 1.03M | 258.00K |
| Depreciation & Amortization | 0.00 | 0.00 | 100.00 | 100.00 | 100.00 |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 206.60K | 399.40K | 171.00K | 1.38M | 576.50K |
| Operating Income | -206.60K | -399.40K | -171.00K | -1.38M | -576.50K |
| Income Before Tax | -260.50K | -346.40K | -1.89M | -1.39M | -566.40K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -260.50K | -346.40K | -1.89M | -1.39M | -566.40K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -260.50K | -346.40K | -1.89M | -1.39M | -566.40K |
| EBIT | -206.60K | -399.40K | -171.00K | -1.38M | -576.50K |
| EBITDA | -206.60K | -399.40K | -170.90K | -1.38M | -576.40K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 418.56M | 418.56M | 418.29M | 388.40M | 357.82M |
| Average Diluted Shares Outstanding | 418.56M | 418.56M | 418.29M | 388.40M | 357.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |